Published in The Lancet | First-in-Class Bispecific ADC Iza-bren Reshapes Clinical Treatment Decision-Making and Ushers in a New Era of Bispecific ADC Therapy for Breast Cancer

Published in The Lancet | First-in-Class Bispecific ADC Iza-bren Reshapes Clinical Treatment Decision-Making and Ushers in a New Era of Bispecific ADC Therapy for Breast Cancer

The 2026 ESMO Congress brought major advances to the forefront of oncology. Iza-bren (BL-B01D1/伦康依隆妥单抗), the world's first-in-class and first approved EGFR×HER3 bispecific antibody–drug conjugate (ADC), made a striking appearance with data from its pivotal Phase III PANKU-Breast01 study. The study presented its prespecified interim analysis results in full for the first time in a late-breaking abstract (LBA).
ESMO Investigator Insights | Professor Qingyuan Zhang: Robust Clinical Evidence Demonstrates the Strength of Iza-bren, Ushering in a New Era of Breast Cancer Treatment

ESMO Investigator Insights | Professor Qingyuan Zhang: Robust Clinical Evidence Demonstrates the Strength of Iza-bren, Ushering in a New Era of Breast Cancer Treatment

The European Society for Medical Oncology (ESMO) Congress is one of the most influential academic events in global oncology, where the presentation of each major study has the potential to reshape the clinical treatment landscape. Iza-bren (伦康依隆妥单抗), a globally pioneering, first-in-class bispecific antibody–drug conjugate (ADC) and the first of its kind to receive regulatory approval worldwide, has demonstrated significant clinical impact. At this year's congress, the interim analysis results of its pivotal Phase III PANKU-Breast01 study were presented as a late-breaking abstract (LBA). The study evaluated patients with unresectable locally advanced or metastatic HR-positive/HER2-negative breast cancer who had received prior endocrine therapy and one to two lines of chemotherapy. The results were also published simultaneously in The Lancet (impact factor: 109), making iza-bren the first innovative Chinese drug in the field of breast cancer to be published in the journal's main edition in its 200-year history.
ESMO Investigator Insights | Professor Shusen Wang: Reshaping the Breast Cancer Treatment Landscape—How Iza-bren Is Ushering in a New Era of Bispecific ADC Therapy

ESMO Investigator Insights | Professor Shusen Wang: Reshaping the Breast Cancer Treatment Landscape—How Iza-bren Is Ushering in a New Era of Bispecific ADC Therapy

The European Society for Medical Oncology (ESMO) Congress is one of the most prestigious academic events in global oncology, where the presentation of every major study has the potential to reshape the clinical treatment landscape. Iza-bren (伦康依隆妥单抗) is the world's first approved EGFR×HER3 bispecific antibody–drug conjugate (ADC). At this year's congress, the pivotal Phase III PANKU-Breast01 study, led by Academician Binghe Xu of the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, was presented as a late-breaking abstract (LBA). The study evaluated iza-bren in patients with unresectable locally advanced or metastatic HR-positive/HER2-negative breast cancer who had previously received endocrine therapy and one to two lines of chemotherapy, and demonstrated highly encouraging results. The full study was also published simultaneously in The Lancet (impact factor: 109), making iza-bren the first innovative Chinese drug in the field of breast cancer to be published in the journal's main edition.
ESMO Investigator Insights | Professor Yehui Shi: Confronting Challenges and Breaking New Ground—How the World’s First Bispecific ADC, Iza-bren, Is Ushering in a New Era of Bispecific ADC Therapy for Breast Cancer

ESMO Investigator Insights | Professor Yehui Shi: Confronting Challenges and Breaking New Ground—How the World’s First Bispecific ADC, Iza-bren, Is Ushering in a New Era of Bispecific ADC Therapy for Breast Cancer

The European Society for Medical Oncology (ESMO) Congress is one of the most highly anticipated academic events in global oncology, where the presentation of every major study has the potential to reshape the clinical treatment landscape. Iza-bren (BL-B01D1/伦康依隆妥单抗) is the world's first approved EGFR×HER3 bispecific antibody–drug conjugate (ADC). At this year's congress, the pivotal Phase III PANKU-Breast01 study evaluating iza-bren in patients with HR-positive/HER2-negative advanced breast cancer who had previously received endocrine therapy and one to two lines of chemotherapy was presented as a late-breaking abstract (LBA), demonstrating impressive results.
2026 East China Breast Cancer Salon | Professor Yongmei Yin: A Decade of Academic Exchange and Mentorship—Advancing Evidence-Based Practice and Standardized Breast Cancer Care

2026 East China Breast Cancer Salon | Professor Yongmei Yin: A Decade of Academic Exchange and Mentorship—Advancing Evidence-Based Practice and Standardized Breast Cancer Care

Against the vibrant autumn backdrop of Nanjing, breast cancer experts gathered on October 11, 2026, for the 2026 East China Breast Cancer Salon. Under the theme “Ninety Years of Compassion and Dedication, Passing the Torch of Medical Excellence,” the meeting focused on advances in breast cancer diagnosis and treatment, clinical implementation, and the development of the specialty. Over the past decade, the salon has established a strong regional foundation while benchmarking its work against international standards, creating an academic platform that integrates cutting-edge research, clinical application, and professional training.
ESMO Preview | ORR of 68% and Median PFS of 11.2 Months: A New First-Line Strategy for la/mUC With Sacituzumab Tirumotecan Plus Immunotherapy

ESMO Preview | ORR of 68% and Median PFS of 11.2 Months: A New First-Line Strategy for la/mUC With Sacituzumab Tirumotecan Plus Immunotherapy

With advances in clinical research and updates to treatment guidelines, antibody–drug conjugate (ADC) combinations with immunotherapy have become a new standard of first-line treatment for locally advanced or metastatic urothelial carcinoma (la/mUC). The 2026 Congress of the European Society for Medical Oncology (ESMO) will be held in Madrid, Spain, from October 23 to 27, local time, featuring numerous cutting-edge studies in genitourinary oncology. Among them, data from a study of sacituzumab tirumotecan (Sac-TMT), a TROP2-targeted ADC developed in China, in first-line advanced urothelial carcinoma have been selected for a rapid oral presentation [1]. Updated results showed a confirmed objective response rate (ORR) of 68%, a median duration of response (DOR) of 19.4 months, and a median progression-free survival (PFS) of 11.2 months. Effective and durable tumor responses were observed regardless of patients' TROP2 and PD-L1 expression levels, suggesting a potential new treatment option for this population. The full text of the regular abstract has now been released. This article summarizes the latest developments and key findings for our readers.
Professor Yonghong Li: New Edition of the China Yearbook of Quality Control for Standardized Prostate Cancer Diagnosis and Treatment Released, With ADT Remaining the Cornerstone of Comprehensive Disease Management

Professor Yonghong Li: New Edition of the China Yearbook of Quality Control for Standardized Prostate Cancer Diagnosis and Treatment Released, With ADT Remaining the Cornerstone of Comprehensive Disease Management

Prostate cancer is one of the most common malignancies threatening men's health. In China, a high proportion of patients are diagnosed at the locally advanced or advanced stage, and overall outcomes continue to lag behind those in developed countries. Improving the overall effectiveness of prostate cancer treatment requires a systematic approach to standardizing and harmonizing diagnosis and treatment nationwide, with quality control for individual diseases serving as a key entry point. Since its establishment in 2021, the Prostate Cancer Quality Control Expert Committee of the National Cancer Center has systematically advanced the development of a quality control framework. The new edition of the China Yearbook of Quality Control for Standardized Prostate Cancer Diagnosis and Treatment (hereafter, the Quality Control Yearbook) was recently released. In an interview with Oncology Frontier, Professor Yonghong Li of Sun Yat-sen University Cancer Center shared her insights into prostate cancer epidemiology, the foundational role of androgen deprivation therapy (ADT), the standardized use of treatments and clinical indicators, and future directions for quality control.
SIBCS 2026 | Professor Jian Zhang: From Adjuvant CDK4/6 Inhibitors to Post-Recurrence Treatment—New Perspectives on Stratified Management of HR+/HER2− Advanced Breast Cancer

SIBCS 2026 | Professor Jian Zhang: From Adjuvant CDK4/6 Inhibitors to Post-Recurrence Treatment—New Perspectives on Stratified Management of HR+/HER2− Advanced Breast Cancer

The 21st Shanghai International Breast Cancer Symposium (SIBCS) was held in Shanghai on October 16–17, 2026. The meeting brought together experts in breast cancer from across China for in-depth discussions on comprehensive breast cancer management and precision, stratified treatment.
From Tumor Metabolic Reprogramming to Immune Evasion: Metabolic Immune Checkpoints Offer a New Framework for Precision Immunotherapy

From Tumor Metabolic Reprogramming to Immune Evasion: Metabolic Immune Checkpoints Offer a New Framework for Precision Immunotherapy

On October 9, 2026, a research team from Zhongnan Hospital of Wuhan University, the Taikang Center for Life and Medical Sciences at Wuhan University, the National Cancer Center, and the Cancer Hospital of the Chinese Academy of Medical Sciences published a review article online in Signal Transduction and Targeted Therapy (impact factor: 81.2), entitled “Metabolic immune checkpoints (MICs) in cancer: from molecular mechanisms to challenges and opportunities in clinical translation.” The review was co-corresponding-authored by Academician Qianjun Xu, Professor Xiehua Xie, and Professor Yechun Yi. It systematically examines the molecular mechanisms through which tumor metabolic reprogramming drives immune evasion and proposes a theoretical framework centered on metabolic immune checkpoints (MICs), offering a new conceptual basis for understanding immunotherapy resistance and developing combined metabolic and immunotherapeutic strategies.
18th Shanghai Breast Reconstruction Conference | Professor Jill Dietz: Lifelong Learning in Oncoplastic Surgery, with MDT Collaboration and Intergenerational Knowledge Transfer as Keys to Progress

18th Shanghai Breast Reconstruction Conference | Professor Jill Dietz: Lifelong Learning in Oncoplastic Surgery, with MDT Collaboration and Intergenerational Knowledge Transfer as Keys to Progress

The 18th Shanghai Breast Reconstruction Conference was held in Shanghai on October 14–15, 2026. The meeting brought together renowned experts from the United States, France, Australia, Germany, the United Kingdom, and other countries and regions to share advanced experience and the latest research in breast reconstruction, specialist training, and interdisciplinary collaboration.